SJM
39
-4
WDC
54
2
HCA
64
2
KEY
62
2
VFC
47
9
GD
62
2
GILD
39
-2
COST
56
-2
LEN
61
2
SWKS
58
6
HPQ
63
3
DRI
58
-2
BF.B
53
2
M
40
4
EXPD
53
2
IP
50
2
LLY
60
-4
TGT
59
2
MCD
68
5
RCL
74
-2
SJM
39
-4
WDC
54
2
HCA
64
2
KEY
62
2
VFC
47
9
GD
62
2
GILD
39
-2
COST
56
-2
LEN
61
2
SWKS
58
6
HPQ
63
3
DRI
58
-2
BF.B
53
2
M
40
4
EXPD
53
2
IP
50
2
LLY
60
-4
TGT
59
2
MCD
68
5
RCL
74
-2
Financhill
Back

Kymera Therapeutics 10K Form

Buy
67

KYMR
Kymera Therapeutics

Last Price:
43.81
Seasonality Move:
-6.51%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KYMR News And Ratings

See the #1 stock for the next 7 days that we like better than KYMR

KYMR Financial Statistics

Sales & Book Value

Annual Sales: $78.59M
Cash Flow: $-47.63M
Price / Cash Flow: 0
Annual Sales: $11.12
Price / Book: 3.97

Profitability

EPS (TTM): -2.42000
Net Income (TTM): $-157.85M
Gross Margin: --
Return on Equity: -30.1%
Return on Assets: -23.18%

Kymera Therapeutics Earnings Forecast

Key Kymera Therapeutics Financial Ratios

  • The Research & Development expenses have been 240.59% of Revenue.
  • The Interest Expense is -0.13% of Operating Income.
  • The Net Earning history of KYMR is -186.99% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Kymera Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KYMR
Website: kymeratx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.45
Quick Ratio: 8.23

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KYMR Technical Analysis vs Fundamental Analysis

Buy
67
Kymera Therapeutics (KYMR) is a Buy

Is Kymera Therapeutics a Buy or a Sell?